Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Ulm – page 30

574 clinical trials in Ulm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ulm at a glance
574
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

574 trials in Ulm

Open in trial search

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Acute myeloid leukaemia

Not recruiting

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Obesity

Not recruiting

Study on Maintaining Weight Loss in Teens with Obesity Using Semaglutide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Acute myeloid leukaemia refractory+3

Not recruiting

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Type 1 diabetes mellitus

Not recruiting

Study on Verapamil SR for Adults with Newly Diagnosed Type 1 Diabetes to Preserve Beta-Cell Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Verapamil Hydrochloride
  • Sponsor:Medical University Of Graz

Bladder transitional cell carcinoma

Not recruiting

Study of Eciskafusp Alfa and BCG for Patients with High-Risk Bladder Cancer Not Responding to BCG Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7284755
  • Sponsor:F. Hoffmann-La Roche AG

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Oropharyngeal squamous cell carcinoma

Not recruiting

Study on Reducing Treatment Intensity for Patients with HPV-Positive Oropharyngeal Cancer Using Cisplatin and Carboplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Cardiff University

Primary mediastinal large B-cell lymphoma

Not recruiting

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Crohn's disease

Not recruiting

Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Ulm

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on colorectal cancer, acute myeloid leukemia, and various types of lymphomas. Studies are evaluating novel combination therapies and targeted treatments for patients with specific genetic mutations.

  • Metastatic Colorectal Cancer Treatment
  • B-Cell Lymphoma Therapies
  • Advanced Breast Cancer Studies

Multiple trials investigating innovative treatment approaches for blood cancers and solid tumors.

02 Neurological Disorders

Clinical research targeting multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. Studies are exploring new therapeutic agents and diagnostic tools.

  • Early-Stage Alzheimer's Treatment
  • Progressive MS Therapies
  • ALS Gene-Targeted Treatments

Innovative approaches in neurodegenerative disease management and treatment.

03 Autoimmune Conditions

Comprehensive studies on inflammatory bowel diseases, rheumatoid arthritis, and Sjögren's disease. Research focuses on novel biological therapies and long-term treatment options.

  • Crohn's Disease Treatments
  • Ulcerative Colitis Management
  • Autoimmune Disorder Therapies

Advanced therapeutic approaches for chronic inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.